When patients with PSA recurrence are treated intermittently with ADT regimens, their disease may behave differently upon relapse. The PSA doubling time after a treatment break can become longer and more favorable, suggesting the therapy may alter the tumor's biology rather than just temporarily suppressing it.
Progress in prostate cancer was historically challenged because trials in the 80s-2000s included a large proportion of patients with low-risk disease (e.g., Gleason 6). These patients didn't require aggressive therapy, which "contaminated" results and made it difficult to discern the true benefit of new treatments for high-risk populations.
A key clinical finding from studies on PTEN-deficient prostate cancer is its potential for disease progression on imaging without a corresponding rise in PSA levels. This discordance necessitates a monitoring strategy that relies on regular imaging, not just PSA, to accurately detect disease advancement in this patient subset.
The PROTEUS trial's control arm was ADT plus placebo, not just surgery, specifically to maintain blinding. This design was crucial for ensuring patient retention and compliance with imaging over the seven-year follow-up, preventing high dropout rates that would have compromised the trial's data integrity.
For patients with metastatic hormone-sensitive prostate cancer (mHSPC), ADT monotherapy is obsolete. The standard of care is a doublet (ADT plus an ARPI) or a triplet (ADT, ARPI, and chemo), as combination therapy has demonstrated significant overall survival benefits. ADT alone should only be used if there are specific contraindications.
The rash associated with apalutamide can be effectively managed with dose reductions, temporary holds, and topical treatments. Unlike many other drug rashes, it does not typically necessitate permanent cessation of therapy, and approximately 90% of patients can successfully restart and remain on the agent.
The informal rule against offering radical prostatectomy to men over 75 stemmed from the era of highly morbid open procedures. Modern robotic surgery, with less blood loss and quicker recovery, makes the operation feasible for older, fit men, shifting the decision from a rigid age cutoff to a more holistic patient assessment.
Historically, prostate cancer care was siloed between surgeons and radiation oncologists, unlike breast cancer's integrated team approach. This lack of collaboration and a unifying figure like Dr. Bernard Fisher, who pioneered randomized trials in breast cancer, held back progress in optimizing treatments for localized disease.
In the PROTEUS trial, adding apalutamide delayed the need for subsequent therapy (like radiation and more hormones) by three years. This endpoint is highly relevant to patients, as it signifies a prolonged period free from the toxicities and lifestyle impact of further treatment, offering a clinical benefit similar to progression-free survival.